Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study

被引:3
|
作者
Elsamany, Shereef Ahmed [1 ,2 ]
Alghanmi, Hossam [3 ]
Albaradei, Abdelrahman [3 ]
Abdelhamid, Rasha [4 ]
Madi, Eman [4 ]
Ramzan, Amira [4 ]
机构
[1] King Abdullah Med City, Oncol Ctr, Muzdalifah Rd, Al Mashair 24246, Makkah, Saudi Arabia
[2] Mansoura Univ, Oncol Ctr, Mansoura, Egypt
[3] King Abdullah Med City, Mecca, Saudi Arabia
[4] King Abdullah Med City, Oncol Ctr, Oncol Nurse, Mecca, Saudi Arabia
关键词
Compliance; Adjuvant; Hormonal therapy; Breast cancer; ADJUVANT ENDOCRINE THERAPY; ADHERENCE; TAMOXIFEN; WOMEN; COHORT; DISCONTINUATION; NONADHERENCE;
D O I
10.1016/j.breast.2022.01.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Adherence to long-term adjuvant hormonal therapy in hormonal receptors (HR)-positive breast cancer is really challenging and can affect the survival outcome. The present study aims to assess rate of compliance with hormonal therapy and possible predictive factors in a single institute in Saudi Arabia. Patients &methods: We recruited patients with HR-positive breast cancer who presented to oncology outpatient clinics. Patients were assessed for compliance using a study questionnaire. Compliance was defined as taking >= 80% of prescribed doses of oral hormonal therapy. Different epidemiological, clinical, pathological and treatment data were checked in patients' medical records and correlated with compliance/interruption of hormonal therapy. Results: Among the 203 recruited patients, 95.1% were compliant with hormonal therapy, while it was interrupted in 16.7% of patients, and 58.1% reported missing intake of hormonal pills. Age >50 years, having permanent job and higher education level were significantly associated with non-compliance in univariate analysis. On multivariate analysis, job status was the only independent predictor of non-compliance. The following parameters were significantly related to hormonal therapy interruption: marital status (single: 28.8% vs married patients: 12.6%, p = 0.01) and residence location (Makkah: 11.7% vs. outside Makkah: 25.3%, p = 0.019), lymphovascular invasion (LVI) (No: 20.9%, Yes: 7.8%, p = 0.025) and NO tumours (compared to node-positive patients, p = 0.008). On multivariate analysis, marital status, residence location and N-stage, maintained significance relation with hormonal therapy interruption. Conclusion: Compliance with hormonal therapy was high in the study cohort. Marital status, residence location, job status and N-stage may be related to interruption/compliance with hormonal therapy.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 50 条
  • [1] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
    Yan, Yi-Dan
    Fu, Jie
    Gu, Zhi-Chun
    Lu, Jin-Song
    Su, Ying-Jie
    Lin, Hou-Wen
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (01) : 184 - 190
  • [2] Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer
    Ayres, Lorena Rocha
    Baldoni, Andre de Oliveira
    Borges, Anna Paula de Sa
    Leira Pereira, Leonardo Regis
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (01) : 45 - 54
  • [3] Adjuvant hormonal therapy for early breast cancer: Assessment of patients' satisfaction
    Vardanega, Julie
    Henriques, Julie
    Pourcelot, Charlotte
    Dirand, Camille
    Nallet, Gilles
    Bredart, Anne
    Anota, Amelie
    Chaigneau, Loic
    Curtit, Elsa
    Limat, Samuel
    Paget-Bailly, Sophie
    Nerich, Virginie
    BULLETIN DU CANCER, 2019, 106 (12) : 1104 - 1114
  • [4] Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer
    Lorena Rocha Ayres
    André de Oliveira Baldoni
    Anna Paula de Sá Borges
    Leonardo Régis Leira Pereira
    International Journal of Clinical Pharmacy, 2014, 36 : 45 - 54
  • [5] Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study
    Fasching, P. A.
    Fehm, T.
    Kellner, S.
    de Waal, J.
    Rezal, M.
    Baler, B.
    Baake, G.
    Kolberg, H. -C
    Guggenberger, M.
    Warm, N.
    Harbeck, N.
    Wuerstlein, R.
    Deuker, J. -U
    Dall, P.
    Richter, B.
    Wachsmann, G.
    Brucker, C.
    Siebers, J. W.
    Fersis, N.
    Kuhn, T.
    Wolf, C.
    Vollert, H. -W
    Breitbach, G. -P
    Janni, W.
    Landthaler, R.
    Kohls, A.
    Rezek, D.
    Nosslet, T.
    Fischer, G.
    Henschen, S.
    Praetz, T.
    Heyl, V.
    Kuehn, T.
    Krauss, T.
    Thomssen, C.
    Kuemmel, S.
    Hohn, A.
    Tesch, H.
    Mundhenke, C.
    Hein, A.
    Rauh, C.
    Bayer, C. M.
    Jacob, A.
    Schmidt, K.
    Belleville, E.
    Hadji, P.
    Wallwiener, D.
    Grischice, E. -M
    Beckmann, M. W.
    Brucker, S. Y.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2014, 74 (12) : 1137 - 1143
  • [6] Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients
    Mao, Daqin
    Hachem, Hilal
    Chang, Hong
    Dima, Danai
    Dower, Joshua
    Wismer, Michael
    Erban, John K.
    Freund, Karen M.
    Parsons, Susan K.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (03) : 665 - 674
  • [7] Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence
    Pourcelot, Charlotte
    Orillard, Emeline
    Nallet, Gilles
    Dirand, Camille
    Billion-Rey, Francois
    Barbier, Garance
    Chouk, Sarah
    Limat, Samuel
    Montcuquet, Philippe
    Henriques, Julie
    Paget-Bailly, Sophie
    Anota, Amelie
    Chaigneau, Loic
    Nerich, Virginie
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (01) : 153 - 162
  • [8] The impact of tamoxifen brand switch on side effects and patient compliance in hormone receptor positive breast cancer patients
    Zeidan, B.
    Anderson, K.
    Peiris, L.
    Rainsbury, D.
    Laws, S.
    BREAST, 2016, 29 : 62 - 67
  • [9] A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer
    Barron, T. I.
    Cahir, C.
    Sharp, L.
    Bennett, K.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1513 - 1521
  • [10] Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)
    Neugut, Alfred I.
    Hillyer, Grace Clarke
    Kushi, Lawrence H.
    Lamerato, Lois
    Leoce, Nicole
    Nathanson, S. David
    Ambrosone, Christine B.
    Bovbjerg, Dana H.
    Mandelblatt, Jeanne S.
    Magai, Carol
    Tsai, Wei-Yann
    Jacobson, Judith S.
    Hershman, Dawn L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 419 - 428